Jason Daly Sells 6,613 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 6,613 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $17.70, for a total value of $117,050.10. Following the transaction, the executive vice president owned 245,171 shares in the company, valued at $4,339,526.70. This trade represents a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $18.15 on Friday. The business has a 50-day simple moving average of $17.24 and a two-hundred day simple moving average of $14.59. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. Amneal Pharmaceuticals, Inc. has a 52 week low of $9.20 and a 52 week high of $19.26. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 37.04 and a beta of 1.27.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AMRX. Westshore Wealth LLC bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley grew its stake in Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after acquiring an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after acquiring an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at $17,573,000. Finally, Penn Capital Management Company LLC purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth $12,655,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on AMRX. The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $17.67.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.